Company: BIVIW
Filing Date: 2025-07-22
Form Type: S-1/A
Source: 0001520138-25-000216
Chunk: 47

Company: BIOVIE INC.
Filing Date: 2025-07-22
Form: S-1/A
Chunk 47
---
 compensation. Conversely, we may not always be able to successfully pursue our claims against others that infringe upon our technology.
Thus, the proprietary nature of our technology or technology licensed by us may not provide adequate protection against competitors, and
we may not be able to prevent competitors from developing and commercializing competitive products or technologies.

In addition, in some circumstances, we may not
have the right to control the preparation, filing and prosecution of patent applications or to maintain, defend and enforce the patents
that we license to or from third parties, and we may have to rely on our partners to fulfill these responsibilities. If our current or
future licensors, licensees or collaborators fail to prepare, file, prosecute, maintain, enforce, and defend licensed patents and other
intellectual property rights, such rights may be reduced or eliminated, and our right to develop and commercialize any of our drug candidates
or technology that are the subject of such licensed rights could be adversely affected. In addition, our licensors may own or control
intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that
we are infringing or otherwise violating the licensor’s rights.

If we fail to comply with our obligations, including
the obligation to make various milestone payments and royalty payments, under any of the agreements under which we license intellectual
property rights from third parties, the licensor may have the right to terminate the license. If any of our license agreements is terminated,
the underlying licensed patents fail to provide the intended exclusivity or we otherwise experience disruptions to our business relationships
with our licensors, we could lose intellectual property rights that are important to our business or be prevented from developing and
commercializing our drug candidates, and competitors could have the freedom to seek regulatory approval of, and to market, products identical
to ours. Termination of these agreements or reduction or elimination of our rights under these agreements may also result in our having
to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our
rights to important intellectual property or technology, or impede, delay or prohibit the further development or commercialization of
one or more drug candidates that rely on such agreements. It is possible that we may be unable to obtain any additional licenses at a
reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign
our drug candidates or the methods